Get the Stockscreener App
2.42
0.41%
-0.01
After Hours:
2.42
Lisata Therapeutics Inc stock is traded at $2.42, with a volume of 12,043.
It is down -0.41% in the last 24 hours and up +10.50% over the past month.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
See More
Previous Close:
$2.43
Open:
$2.38
24h Volume:
12,043
Relative Volume:
0.30
Market Cap:
$21.19M
Revenue:
-
Net Income/Loss:
$-20.74M
P/E Ratio:
-0.9641
EPS:
-2.51
Net Cash Flow:
$-18.90M
1W Performance:
-2.02%
1M Performance:
+10.50%
6M Performance:
+23.47%
1Y Performance:
-17.12%
1-Day Range:
$2.3753
$2.4283
1-Week Range:
$2.32
$2.6199
52-Week Range:
$1.87
$4.20
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Name
Lisata Therapeutics Inc
Sector
Industry
Phone
908-229-2590
Address
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
2.42 | 21.28M | 0 | -20.74M | -18.90M | -2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lisata Therapeutics Inc Stock (LSTA) Latest News
Lisata Therapeutics Highlights Cancer Therapy Innovations - TipRanks
Lisata Therapeutics, Inc. Issues Investor Presentation - TradingView
Is Lisata Therapeutics Inc. (8NE) stock nearing a technical breakoutQuarterly Investment Review & Advanced Technical Signal Analysis - newser.com
Using data filters to optimize entry into Lisata Therapeutics Inc.July 2025 Sector Moves & Risk Controlled Stock Alerts - newser.com
Can Lisata Therapeutics Inc. stock weather global recession2025 Geopolitical Influence & Advanced Technical Analysis Signals - newser.com
Lisata to present at LD Micro Main Event XIX Conference - Proactive financial news
Lisata Therapeutics to Present at LD Micro Main Event XIX - Stock Titan
How Lisata Therapeutics Inc. (8NE) stock trades pre earningsQuarterly Performance Summary & Reliable Price Breakout Signals - newser.com
What does recent volatility data suggest for Lisata Therapeutics Inc.July 2025 Drop Watch & Consistent Growth Stock Picks - newser.com
Lisata Therapeutics CEO discusses Catalent dealICYMI - Proactive financial news
Real time scanner hits for Lisata Therapeutics Inc. explainedEarnings Recap Summary & Daily Profit Maximizing Trade Tips - newser.com
Lisata Therapeutics Inc. recovery potential after sell offJuly 2025 Summary & Daily Stock Momentum Reports - newser.com
Lisata Therapeutics CEO Dr David Mazzo on global product license deal with Catalent - Proactive financial news
Lisata Therapeutics Partners with Catalent on ADC Technology - Yahoo Finance
CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drug - Fierce Biotech
What moving averages say about Lisata Therapeutics Inc.2025 Biggest Moves & Weekly Watchlist for Hot Stocks - newser.com
Is Lisata Therapeutics Inc. (8NE) stock resilient in recession scenariosMarket Growth Report & Breakout Confirmation Trade Signals - newser.com
Can volume confirm reversal in Lisata Therapeutics Inc.July 2025 Reactions & Short-Term High Return Strategies - newser.com
Lisata Therapeutics enters non-exclusive license agreement with Catalent By Investing.com - Investing.com South Africa
Lisata Therapeutics enters non-exclusive license agreement with Catalent - Investing.com India
Lisata Therapeutics Signs License Agreement with Catalent - TipRanks
Lisata Therapeutics Lands Major Licensing Deal as Catalent Taps Certepetide for Global ADC Program - citybiz
Small cap wrap: GoviEx Uranium, Lisata Therapeutics, Bit Digital, Alvopetro Energy... - Proactive financial news
Lisata Therapeutics (LSTA) Licenses Certepetide to Catalent for Advanced Cancer Therapies - GuruFocus
Lisata Therapeutics and Catalent announce global antibody-drug conjugate license agreement - MarketScreener
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement - GlobeNewswire
$10M+ Milestones: Lisata Licenses Certepetide to Catalent for SMARTag® ADC Development - Stock Titan
Lisata Therapeutics inks global product license deal with Catalent - Proactive financial news
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events | News | postregister.com - FinancialContent
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events - FinancialContent
Can Lisata Therapeutics Inc. stock resist sector downturnsPortfolio Update Summary & Real-Time Chart Pattern Alerts - newser.com
Sentiment analysis tools applied to Lisata Therapeutics Inc.Market Growth Report & Breakout Confirmation Trade Signals - newser.com
How to recover losses in Lisata Therapeutics Inc. stock2025 Market Sentiment & Expert Verified Movement Alerts - newser.com
What insider purchases suggest about Lisata Therapeutics Inc. (8NE) stock2025 Institutional Moves & Free Daily Entry Point Trade Alerts - newser.com
Why Lisata Therapeutics Inc. (8NE) stock fits value portfoliosQuarterly Growth Report & Stepwise Trade Signal Guides - newser.com
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Invest In Growth? - Yahoo Finance
When is the best time to exit Lisata Therapeutics Inc.Portfolio Gains Report & Risk Controlled Stock Pick Alerts - newser.com
Lisata Therapeutics Inc Stock (LSTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):